How Often Should You Get NAD+ IV Therapy? The Question That Decides Whether the Series Finishes

A patient finishes her first NAD+ infusion, picks up her bag, and asks the only question that determines whether she ever comes back.

"So how often should I be doing this?"

Nicotinamide adenine dinucleotide is not an FDA-approved drug. It reaches U.S. clinics as a compounded preparation, and on the Food and Drug Administration's list of bulk drug substances nominated for compounding under section 503A, updated 14 May 2026, NAD sits in Category 1, "Bulk Drug Substances Under Evaluation." There is no approved label to read the dosing interval off, because there is no approved label. The largest published human study of intravenous NAD+, run at Springfield Wellness Center and published in Frontiers in Aging Neuroscience in 2019, enrolled eleven men. Eight of them received NAD+.

So when the front desk answers that question, it is not retrieving a fact. It is either reciting the clinic's own written protocol, or improvising. There is no third option.

No clinical trial establishes an optimal NAD+ infusion frequency, and the published protocols came from clinics rather than the literature

This deserves stating precisely, because it is the root of the operational problem.

The pharmacokinetic study by Grant and colleagues, published in Frontiers in Aging Neuroscience in 2019, administered 750 mg of NAD+ in normal saline over six hours to eight healthy men aged 30 to 55. It found no change in plasma NAD+ or its metabolites until after the two-hour mark. It did not establish a clinical outcome, a benefit, or a dosing schedule. The authors are explicit about where their dose came from: "This dosage of NAD+ was derived empirically and reflects a common dosing regimen in clinics."

That sentence is worth reading twice. The research dose was copied from clinic practice. Clinic practice was not derived from the research.

The only real-world tolerability comparison published since is a retrospective review of electronic records at RestoreLabs, Restore Hyperwellness in Austin, Texas, published in Frontiers in Aging in February 2026. It covered six NAD+ clients and eight receiving nicotinamide riboside, on a protocol of 500 mg over four consecutive days. NAD+ infusions averaged 97 minutes with a standard deviation of 56 minutes. Seven of the authors were employed by Restore Hyperwellness and the comparator product was donated by Niagen Biosciences, which should be weighed when reading it. The authors' own summary of the gap is the relevant line: "Anecdotal strategies such as using slow, prolonged infusions have been proposed, but formal studies are lacking."

A systematic review in the American Journal of Physiology-Endocrinology and Metabolism in 2024 pooled ten randomised trials and 489 participants, but its conclusions concern oral NADH, not intravenous NAD+. It is not evidence for infusion cadence and should not be cited as though it were.

Named clinics do publish cadences, and they agree with each other more than the evidence base would predict

Because there is no authoritative answer, each clinic has written its own. Reading them side by side is instructive.

• IV Elements, in New Jersey, publishes a twelve-week schedule: two to three sessions a week for the first two weeks, tapering to one or two a week by week four, then maintenance every other week through week twelve. Elsewhere on the same page: "A typical NAD IV maintenance schedule includes one session every 2 to 6 weeks."

• Modal Pain Management in Manhattan publishes three named loading protocols, including "Standard loading: 250 mg twice weekly for 2 weeks, then weekly for 2 weeks," followed by maintenance "every 4 to 8 weeks."

• Dripology publishes "a loading series of three to six sessions over two to three weeks, then move to a maintenance cadence of one session every four to six weeks."

• LIVV Natural in San Diego publishes "once a week for four weeks, once a month for 5 months, once a quarter for your lifetime."

• Springfield Wellness Center describes an outpatient programme that "typically requires 10 days."

Different cities, different clinicians, no shared trial to work from, and yet the shape converges: roughly one to three infusions a week for two to four weeks, or a run of consecutive days, then maintenance somewhere between every two and every eight weeks.

And then there is the other group. Under the heading "How often should you do NAD drip treatments?", Regenerative Medicine LA answers: "The frequency of NAD drip treatments depends on individual needs and health goals... Consulting with a healthcare provider can help determine the most suitable treatment schedule for you." California Infusion Centers: "The ideal frequency varies based on your health goals and the guidance of your clinician." Prime IV Hydration: "For general wellness, periodic sessions are sufficient."

Those are not answers. They are the written form of what a front desk says when nobody has given it a number to say.

Nobody has measured NAD+ series dropout, but the multi-visit protocols that have been measured show heavy non-completion

There is no published NAD+ series-completion or dropout figure. Saying so is more useful than inventing one.

What does exist is a consistent picture from adjacent multi-visit protocols, all named and peer-reviewed:

• A private ketamine clinic study published in the South African Journal of Psychiatry in 2024 reviewed 154 patient files and 863 infusions. Sixty-seven patients, 43.5 percent, completed the six-infusion induction series. Patients paid cash per infusion, with a discount for paying for the series up front.

• A 2025 survey in Patient Related Outcome Measures found that of 193 patients prescribed two or more intravenous iron infusions a month, 71 of them, 36.8 percent, missed at least one dose. Eighty percent reported having to schedule their life around therapy.

• Among 366,103 Medicare beneficiaries studied in Circulation: Cardiovascular Quality and Outcomes in 2020, only 26.9 percent of those who started cardiac rehabilitation completed 36 or more sessions.

And when patients are asked why they stopped, the reasons are operational rather than clinical. In a 2025 study in Musculoskeletal Science and Practice, 26 patients who attended an initial evaluation and never returned cited access issues, 26.9 percent, and not seeing value, 23.1 percent, ahead of anything else. A Mayo Foundation chart review published in 1999 found the commonest reasons for immunotherapy dropout included inconvenience, with roughly 1 percent quitting because of reactions. The author's conclusion: "many of our dropouts were predictable and avoidable."

Three levers have measured effects on completion, and an intake system controls all three

This is where the evidence gets genuinely actionable.

Protocol length. A retrospective multi-centre Italian review published in BioMed Research International in 2020 examined adherence to the same allergen immunotherapy product across seven centres, backtracked from manufacturer refill data. One hundred and fifty-two patients on an abbreviated four-injection build-up were compared with 302 on the traditional seven-injection build-up. One-year dropout was 9.1 percent against 46.4 percent. Reimbursement status was also a significant driver in the same analysis, so the visit count is not the sole explanation, but it is the variable a clinic controls.

Telling patients the course length before they start. A randomised trial published in Psychotherapy Research in 2011 gave one group information about expected treatment length prior to intake. That group stayed in treatment significantly longer and was 3.55 times more likely to be classified as completers. Randomised, not observational.

Booking friction. An analysis of 51,529 appointments at the University of Virginia, published in Clinical Ophthalmology in 2015, found no-show rates of 9.1 percent when appointments were booked within two weeks against 38.3 percent at six-month lead times.

Set those three against the NAD+ caller. She asks how often. If the answer is "it depends, we can talk about it at your next visit," she has been told nothing about course length at exactly the moment the randomised evidence says telling her matters most. If the next available slot is five weeks out because a NAD+ chair is blocked for an unpredictable ninety minutes to four hours, she is being booked into the lead-time band where measured no-shows more than quadruple.

Neither of those is a clinical failure. Both are intake failures, and both are fixable this quarter.

The price question has the same shape as the frequency question, and most clinics answer neither

Published single-infusion pricing at named clinics for a 500 mg dose runs from $275 at Primary Prevention Center in Newtown, Pennsylvania, to $999 at Dripology. That is a spread of roughly three and a half times for the same nominal dose.

Series pricing is scarcer still. IV Elements publishes a three-day package at $1,500 and a ten-day at $10,600. The Remedy Room in New Orleans publishes a three-day at $4,140 and a ten-day at $15,900. Modal Pain declines outright: "Series and package pricing: Discussed at consultation."

Of the named clinics with published NAD+ menus, only a minority publish what a full course costs. So a patient who wants to know what the whole protocol will cost her, which is the same patient asking how often she needs to come, generally cannot find out without a phone call. If that call is not answered, or is answered by someone without the protocol in front of them, the clinic has lost a multi-thousand-dollar series to a question it already knew the answer to.

This is the identical failure documented in the diagnostic panel price call and in peptide therapy pricing. Same caller, same unanswered question, different service line.

What a structured intake layer actually does here, and what it does not

It does not decide the protocol. The clinician does that, once, in writing.

What it does is make sure the clinic's written protocol, rather than an improvised answer, is what the patient is most likely to hear when she asks, including outside clinic hours. It states the clinic's published loading series and maintenance interval in the clinic's own words. It books the next appointment in the series before the patient leaves the current one, which pulls the booking into the short lead-time band. It flags a patient who has drifted past her stated maintenance interval into a reactivation sequence rather than letting her quietly become a churn statistic. And it holds the honest line on what is and is not known, which in this category is a credibility asset rather than a liability.

Your infusion nurse and your patient coordinator are the reason people come back. They should not also be the reason a Saturday caller reaches voicemail. This is amplification of a front desk, not a replacement for one. Aurora, our vitality specialist, is built for exactly this vertical, and the economics of an empty infusion lounge chair are the other half of the same problem: the frequency question fills the chair, the backfill protocol stops it emptying. The multi-visit lab sequence dropoff is the diagnostic-side version of the same leak.

You already know your protocol. You already know what a completed series is worth. The only open question is whether the person who answers at 7pm on a Saturday knows both.

Frequently asked questions

How often should you get NAD+ IV therapy? No clinical trial establishes an optimal frequency. Among named clinics that publish a protocol, the common pattern is a loading phase of roughly one to three infusions per week for two to four weeks, or a run of consecutive days, followed by maintenance every two to eight weeks. Individual protocols are set by the treating clinician, and this article does not recommend one.

How long does a NAD+ IV infusion take? Published durations at named clinics for a 500 mg dose range from roughly 90 minutes at California Infusion Centers to four hours at Dripology and Cienega Med Spa. In the 2026 Restore Hyperwellness record review, 500 mg infusions averaged 97 minutes with a standard deviation of 56 minutes, because the rate is titrated to individual tolerance. The 2019 pharmacokinetic study infused 750 mg over six hours.

Why does NAD+ IV take so long? The clinics that publish a reason give the same one. Modal Pain Management: "The infusion rate is slow on purpose - rapid administration causes substantial discomfort."

Is NAD+ IV therapy FDA approved? No. There is no FDA-approved NAD+ drug product. NAD appears in Category 1, "Bulk Drug Substances Under Evaluation," on the FDA's 503A list updated 14 May 2026 and its 503B list updated 21 March 2025, meaning FDA has not made a final determination and compounding proceeds under an interim enforcement policy the agency has reserved the right to withdraw. NAD is not in Category 2, the category for substances FDA has identified as raising significant safety risks. Two caveats for completeness: beta-nicotinamide adenine dinucleotide disodium salt trihydrate, a specific salt form, sits in Category 3 on both lists, and in 2017 FDA's Pharmacy Compounding Advisory Committee recommended against adding NAD to the 503A list following a nomination for an oral capsule.

How much does a NAD+ IV series cost? Published series pricing at named clinics ranges widely: IV Elements lists $1,500 for three days and $10,600 for ten; The Remedy Room lists $4,140 for three days and $15,900 for ten. Many clinics do not publish series pricing at all.

References

• U.S. Food and Drug Administration, "Bulk Drug Substances Nominated for Use in Compounding Under Section 503A," updated 14 May 2026; and "Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A," Federal Register, 7 January 2025.

• Grant R, Berg J, Mestayer R, et al. "A Pilot Study Investigating Changes in the Human Plasma and Urine NAD+ Metabolome During a 6 Hour Intravenous Infusion of NAD+." Frontiers in Aging Neuroscience, 2019;11:257. n=11 (8 test, 3 control).

• Reyna K, et al. Frontiers in Aging, 2 February 2026;7. Retrospective record review, RestoreLabs / Restore Hyperwellness, n=6 NAD+ and n=8 NR. Seven authors employed by Restore Hyperwellness; comparator product donated by Niagen Biosciences.

• Gindri IM, et al. American Journal of Physiology-Endocrinology and Metabolism, 2024;326(4):E417-E427. Systematic review, 10 randomised trials, 489 participants, oral NADH.

• Caruso C, et al. BioMed Research International, 2020, article 7328469. Retrospective multi-centre review across seven Italian centres, backtracked from manufacturer refill data; 152 patients on an abbreviated 4-injection build-up versus 302 on the traditional 7-injection; one-year dropout 9.1 versus 46.4 percent. Reimbursement status also significant.

• Swift JK, Callahan JL. "Decreasing treatment dropout by addressing expectations for treatment length." Psychotherapy Research, 2011;21(2):193-200. Randomised, n=63; completer relative risk 3.55.

• McMullen MJ, Netland PA. "Lead time for appointment and the no-show rate in an ophthalmology clinic." Clinical Ophthalmology, 2015;9:513-516. 51,529 appointments.

• Juby et al. South African Journal of Psychiatry, 2024;30:2176. 154 patient files, 863 ketamine infusions; 43.5 percent completed the six-infusion induction.

• Lee EJ, et al. Patient Related Outcome Measures, 2025;16. n=323 surveyed; 193 prescribed two or more IV iron infusions monthly.

• Ritchey MD, et al. Circulation: Cardiovascular Quality and Outcomes, 2020;13(1). 366,103 Medicare beneficiaries.

• Thomas AC, et al. Musculoskeletal Science and Practice, 2025;77:103326. Rhodes BJ. Annals of Allergy, Asthma and Immunology, 1999;82(3):281-286.

• Published clinic protocols and pricing read 6 August 2026: IV Elements, Modal Pain Management, Dripology, LIVV Natural, Primary Prevention Center, Springfield Wellness Center, The Remedy Room, Regenerative Medicine LA, California Infusion Centers, Prime IV Hydration.

Next Step

If your premium practice runs more than 100 inbound consult inquiries a month and has no structured measurement of how many never reach a scheduled consultation, your pipeline is leaking revenue. We quantify this for your practice in a 30-minute Intake Leak Audit.

• Request an Intake Leak Audit: expand@thethinkingrobot.com

• Audit Real-Time Conversational Velocity: Talk to Rosey, our AI receptionist, at +1 (720) 776-1664.